Transmedics Group Stock Price, News & Analysis

TransMedics (Nasdaq: TMDX), a medical technology company focused on organ transplant therapy, has announced its participation in two major investor conferences in June 2025. The company will present at the William Blair 45th Annual Growth Stock Conference in Chicago on June 3 at 5:00 p.m. EST and participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami on June 9 at 8:00 a.m. EST. Both presentations will be available via webcast on TransMedics' investor relations website.

TransMedics (NASDAQ: TMDX) reported strong Q1 2025 financial results with total revenue of $143.5 million, up 48% year-over-year. The company achieved a net income of $25.7 million ($0.70 per diluted share) and maintained a robust gross margin of 61%. Growth was primarily driven by increased utilization of their Organ Care System (OCS), particularly in Liver and Heart transplants through the National OCS Program. The company owned 21 aircraft and announced plans for a new design center and manufacturing facility in Italy. Based on strong performance, TransMedics raised its full year 2025 revenue guidance to $565-585 million, representing 30% growth at the midpoint. The company ended Q1 with a strong cash position of $310.1 million.

TransMedics Group (Nasdaq: TMDX), a medical technology company focused on organ transplant therapy, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.

The company will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on the same day. Investors can participate by dialing (844) 676-6010 (domestic) or (412) 634-6944 (international). A live and archived webcast will be available on the company's investor relations website.

TransMedics Group (TMDX) announced the granting of inducement awards to three new employees on March 28, 2025. The compensation package includes:

• 1,570 non-qualified stock options with an exercise price of $68.58 per share
• 1,043 restricted stock units (RSUs)

The stock options will vest 25% after one year, with the remaining vesting monthly over three years. The RSUs will vest 25% annually over four years. Both grants require continued employment and were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4) through the TransMedics Inducement Plan.

TransMedics (TMDX) reported strong financial results for Q4 and full year 2024. The company achieved total revenue of $121.6 million in Q4 2024, up 50% year-over-year, and full-year revenue of $441.5 million, representing an 83% increase from 2023.

Key highlights include net income of $6.9 million ($0.19 per diluted share) in Q4 and $35.5 million ($1.01 per diluted share) for the full year 2024. The company completed 3,715 U.S. OCS cases in 2024, a 58% increase from 2023, and achieved a 20.9% overall OCS market share across all organs.

For 2025, TransMedics projects revenue between $530-552 million, representing 20-25% growth. The company maintained a strong cash position of $336.7 million as of December 31, 2024.

TransMedics Group (Nasdaq: TMDX), a medical technology company focused on transforming organ transplant therapy, has announced its participation in two major investor conferences in March 2025. The company will present at:

1. The TD Cowen 45th Annual Health Care Conference in Boston on March 3, 2025, at 11:50 a.m. EST

2. The Oppenheimer 35th Annual Healthcare MedTech & Services Conference virtually on March 17, 2025, at 9:20 a.m. EST

Interested parties can access live and archived webcasts of both presentations through the 'Investors' section of TransMedics' website. The company's standard investor presentation will also be available through the same platform.

TransMedics Group (Nasdaq: TMDX), a medical technology company focused on organ transplant therapy, has announced it will release its fourth quarter and full year 2024 financial results after market close on Thursday, February 27, 2025. The company will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on the same day to discuss the results.

Investors can participate in the conference call by dialing (844) 481-2832 (domestic) or (412) 317-1852 (international). A live and archived webcast will be available on the company's investor relations website.

TransMedics Group (TMDX) has announced the granting of inducement awards to three new employees on January 28, 2025. The compensation package includes:

- 34,884 non-qualified stock options with an exercise price of $67.03 (closing price on grant date)
- 23,192 restricted stock units (RSUs)

The stock options will vest 25% after one year, with the remainder vesting monthly over three years. They have a 10-year term. The RSUs will vest 25% annually over four years. Both grants are subject to continued employment and were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4) through the TransMedics Group Inducement Plan.

TransMedics Group (TMDX) has issued a strong rebuttal to a short-seller report published by Scorpion Capital on January 10, 2025. The company firmly denies the report's claims, stating they are inaccurate and aimed at market manipulation for financial gain.

The company emphasizes that their OCS™ technology and NOP™ program have facilitated over 7,000 organ transplants, enabling the use of donor organs that would have otherwise gone unused due to technological and logistical limitations. TransMedics has engaged legal counsel at Kirkland & Ellis LLP to evaluate legal options.

The company remains committed to its 2025 growth plans, including the launch of next-gen OCS Heart and OCS Lung programs. Management will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025.